Lapatinib [250 mg tablet] for the treatment of HER2-positive breast cancer
Pre-Cycle 1 | DrugsHTA Council Recommendation (as of 16 June 2021)
As final recommendation, the HTA Council does not recommend the inclusion of lapatinib [250 mg tablet] for the treatment of HER2-positive breast cancer in the Philippine National Formulary (PNF).
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should lapatinib [250 mg tablet] for the treatment of HER2-positive breast cancer be included in the Philippine National Formulary?
- Secretary of Health Decision: Approved as of 23 June 2021
Evidence and Relevant Documents